Please use this identifier to cite or link to this item:
|Title:||Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection||Authors:||Rial, Marcela Silvina
Scalise, María Luján
López Alarcón, Micaela
Esteva, Mónica Inés
Benatar, Alejandro Francisco
Prado, Nilda Graciela
Riarte, Adelina Rosa
Fichera, Laura Edith
|Keywords:||Tratamiento Enfermedad de Chagas;Trypanosoma cruzi||Issue Date:||2019||Journal:||Parasitology||Abstract:||
This study evaluated the effectiveness of low doses of benznidazole (BNZ) on continuous administration (BNZc), combined with allopurinol (ALO), in C57BL/6J and C3H/HeN mice infected with Trypanosoma cruzi Nicaragua strain and T. cruzi Sylvio-X10/4 clone. TcN-C57BL/6J was also treated with intermittent doses of BNZ (BNZit). The drug therapy started 3 months post infection (pi) in the chronic phase of mice with heart disease progression, followed-up at 6 months pi. TcN-C57BL/6J treated with BNZc was also monitored up to 12 months pi by serology and electrocardiogram. These mice showed severe electrical abnormalities, which were not observed after BNZc or BNZit. ALO only showed positive interaction with the lowest dose of BNZ. A clear parasitic effect, with significant reductions in antibody titres and parasitic loads, was achieved in all models with low doses of BNZ, and a 25% reduction of the conventional dose showed more efficacy to inhibit the development of the pathology. However, BNZ 75 showed partial efficacy in the TcSylvio-X10/4-C3H/HeN model. In our experimental designs, C57BL/6J allowed to clearly define a chronic phase, and through reproducible efficacy indicators, it can be considered a good preclinical model.
|Appears in Collections:||Publicaciones INP|
Show full item record
checked on Jul 4, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.